Neuren Pharmaceuticals Dirección

Dirección controles de criterios 3/4

El CEO de Neuren Pharmaceuticals es Jon Pilcher , nombrado en May 2020, tiene una permanencia de 4.5 años. compensación anual total es A$1.36M, compuesta por 40.2% salario y 59.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.31% de las acciones de la empresa, por valor de A$4.95M. La antigüedad media del equipo directivo y de la junta directiva es de 4.4 años y 6.3 años, respectivamente.

Información clave

Jon Pilcher

Chief Executive Officer (CEO)

AU$1.4m

Compensación total

Porcentaje del salario del CEO	40.2%
Permanencia del CEO	4.5yrs
Participación del CEO	0.3%
Permanencia media de la dirección	4.4yrs
Promedio de permanencia en la Junta Directiva	6.3yrs

Actualizaciones recientes de la dirección

Recent updates

New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Nov 11

Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Nov 08

Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Oct 24

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Aug 29

Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Aug 14

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

May 31

Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

May 03

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Apr 01

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Mar 05

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Mar 02

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Dec 18

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Sep 02

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Aug 31

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Mar 03

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Jan 07

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Sep 06

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

May 31

We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Feb 03

Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

Aug 06

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

May 05

Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Feb 19

Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

Jan 04

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jon Pilcher en comparación con los beneficios de Neuren Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	AU$117m
Mar 31 2024	n/a	n/a	AU$137m
Dec 31 2023	AU$1m	AU$549k	AU$157m
Sep 30 2023	n/a	n/a	AU$106m
Jun 30 2023	n/a	n/a	AU$55m
Mar 31 2023	n/a	n/a	AU$28m
Dec 31 2022	AU$546k	AU$396k	AU$184k
Sep 30 2022	n/a	n/a	-AU$3m
Jun 30 2022	n/a	n/a	-AU$7m
Mar 31 2022	n/a	n/a	-AU$7m
Dec 31 2021	AU$432k	AU$203k	-AU$8m

Compensación vs. Mercado: La compensación total ($USD889.38K) de Jon está en línea con el promedio de empresas de tamaño similar en el mercado Australian ($USD1.10M).

Compensación vs. Ingresos: La compensación de Jon ha aumentado más de un 20% en el último año.

CEO

Jon Pilcher

4.5yrs

Permanencia

AU$1,364,404

Compensación

Mr. Jonathan Charles Pilcher, also known as Jon, BSc (Hons), ACA, FCA serves as Managing Director & Executive Director at Neuren Pharmaceuticals Limited since June 14, 2021. He had been a Company Secretary...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jonathan Pilcher	CEO, MD & Executive Director	4.5yrs	AU$1.36m	0.31% A$ 5.5m
Lauren Frazer	CFO & Company Secretary	4.3yrs	sin datos	sin datos
Lawrence Glass	Chief Science Officer	20.8yrs	sin datos	sin datos
Gerry Zhao	Vice President of Corporate Development	no data	sin datos	sin datos
Liza Squires	Chief Medical Officer	2.3yrs	sin datos	sin datos

4.4yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de NEU se considera experimentado (4.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jonathan Pilcher	CEO, MD & Executive Director	3.4yrs	AU$1.36m	0.31% A$ 5.5m
Dianne Angus	Independent Non-Executive Director	6.3yrs	AU$75.00k	0.023% A$ 410.7k
Jenny Harry	Independent Non-Executive Director	6.3yrs	AU$75.00k	0.023% A$ 406.1k
Patrick Donald Davies	Independent Non-Executive Chairman	6.3yrs	AU$125.00k	0.21% A$ 3.6m
Joe Basile	Independent Non-Executive Director	1.7yrs	AU$62.50k	0.017% A$ 293.1k

6.3yrs

Permanencia media

Junta con experiencia: La junta directiva de NEU se considera experimentada (6.3 años de antigüedad promedio).

Neuren Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024

Independent Non-Executive Director recently sold AU$15m worth of stock

Neuren Pharmaceuticals Appoints Liza A. Squires as Chief Medical Officer in United States

Independent Non-Executive Director recently bought AU$59k worth of stock

High number of new directors

Independent Non-Executive Chairman recently bought AU$61k worth of stock

Recent updates

Now 24% undervalued

New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Investor sentiment improves as stock rises 17%

Consensus revenue estimates increase by 17%, EPS downgraded

New major risk - Revenue and earnings growth

Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

First half 2024 earnings: EPS misses analyst expectations

Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Price target decreased by 7.5% to AU$26.54

New major risk - Revenue and earnings growth

Investor sentiment deteriorates as stock falls 15%

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

Price target increased by 7.9% to AU$28.19

Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome

Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Consensus revenue estimates increase by 15%

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Price target increased by 27% to AU$24.22

Investor sentiment improves as stock rises 40%

Consensus EPS estimates fall by 11%

Investor sentiment improves as stock rises 20%

Now 23% undervalued after recent price drop

Price target increased by 18% to AU$19.14

Now 20% undervalued after recent price drop

Consensus revenue estimates increase by 24%

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Now 25% undervalued after recent price drop

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023

Neuren Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 21% undervalued

Consensus EPS estimates fall by 12%

Price target increased by 8.3% to AU$15.07

Independent Non-Executive Director recently sold AU$15m worth of stock

Consensus revenue estimates increase by 12%, EPS downgraded

Price target increased by 18% to AU$10.60

Consensus EPS estimates fall by 14%

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Price target increased by 12% to AU$8.99

Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDA

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Neuren Pharmaceuticals Submits Investigational New Drug & First Patients Complete Phase 2 Trials

Price target increased to AU$7.83

Price target increased to AU$7.83

Price target increased to AU$7.37

Neuren Pharmaceuticals Reports Rett Syndrome New Drug Application Accepted for Priority Review by US Food and Drug Administration

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Neuren Pharmaceuticals Limited Commences Phase 2 Trials of NNZ-2591 in PMS and PTHS

Consensus estimates of losses per share improve by 47%

Price target increased to AU$6.62

Neuren Pharmaceuticals Limited Commences Phase 2 Trial of NNZ-2591 in Angelman

Neuren Pharmaceuticals Appoints Liza A. Squires as Chief Medical Officer in United States

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

Forecast breakeven date pushed back to 2023

Forecast breakeven date pushed back to 2023

Neuren Pharmaceuticals Limited Receives FDA Approval for Angelman IND and Phase 2 Trial

Consensus forecasts updated

We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Independent Non-Executive Director recently bought AU$59k worth of stock

Neuren Pharmaceuticals Submits Investigational New Drug Application to the US Food and Drug Administration for NNZ-2591

Neuren Pharmaceuticals Limited announced that it expects to receive AUD 20.000001 million in funding

Neuren Pharmaceuticals Limited Submits an Investigational New Drug (IND) Application to the US Food and Drug Administration (FDA) for NNZ-2591 to Treat Angelman Syndrome